27 July 2021 | News
The new appointments will provide additional thrust to Emcure’s growth trajectory
Image Credit: Shutterstock
Emcure Pharmaceuticals has recently added four independent directors with a wealth of knowledge and experience in various fields. The new additions include Dr Shailesh Ayyangar, Vijay Gokhale, Hitesh Jain and Dr Vidya Yeravdekar. Earlier this year, Berjis Desai had taken over the chairman of Emcure Board. The company has had a long-standing tradition of appointing a Chairman from amongst its independent directors since 1997.
The additions to the leadership team for Emcure Pharmaceuticals, reflect its commitment towards enriching its expertise and strengthening its operations for future growth. The new members’ collective strength across legal, pharma spectrum, policy developments and academics will provide additional thrust to Emcure’s growth trajectory.
Commenting on the appointments, Satish Mehta, MD and CEO, Emcure Pharmaceuticals said, “We are delighted to have highly accomplished industry stalwarts as part of our board. New members’ combined experience and wider perspective from their respective fields, will play an instrumental role in strengthening our strategic operations to grow in domestic and international markets. It is an exciting time for the organisation, and we look forward to achieving newer heights with our new members on board.”
Emcure’s Chairman and Independent Director, Desai has been associated with Emcure Pharmaceuticals for over three decades. Dr Ayyangar appointed as Additional Director comes with an extensive experience of 34 years in healthcare and pharmaceutical. Gokhale appointed as Independent Director was in the Indian Foreign Service since 1981. Jain, appointed as Independent Director, is an alumnus of London School of Economics in 1996 and Dr Vidya Yeravdekar appointed as Independent Director is the Principal Director of Symbiosis Society, and the Pro-Chancellor of Symbiosis International University.